{"id":18771,"date":"2020-02-11T17:33:00","date_gmt":"2020-02-11T17:33:00","guid":{"rendered":"https:\/\/technopolis-group.com\/can-product-development-partnerships-tackle-diseases-of-the-poor\/"},"modified":"2020-04-08T14:26:16","modified_gmt":"2020-04-08T14:26:16","slug":"can-product-development-partnerships-tackle-diseases-of-the-poor","status":"publish","type":"post","link":"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/","title":{"rendered":"Can Product Development Partnerships tackle diseases of the poor?"},"content":{"rendered":"\n<figure class=\"wp-block-pullquote\"><blockquote><p>The economics of the pharmaceuticals and other healthcare industries are stacked against poor people, who offer unattractive economic returns to investors. Product Development Partnerships (PDPs) aim to break this economic vicious circle. They may also serve developed countries\u2019 interests. As the Ebola epidemic and the slow spread of antibiotic-resistant tuberculosis (TB) show, sometimes the diseases of the poor pose a risk of also becoming diseases of the rich. <\/p><\/blockquote><\/figure>\n\n\n\n<p>It is\neconomically unattractive for pharmaceutical and healthcare products companies\nto address markets where consumers cannot afford to pay much for treatments and\nwhere the volume of demand may be limited because diseases are unusual. Some of\nthe diseases involved in fact affect millions of people but inability to pay\nlimits the number of innovators aiming to tackle them. In addition to the \u2018big\nthree diseases of the developing world (HIV\/ AIDS, TB and malaria) infectious\ndiseases like sleeping sickness, Chagas disease or hookworm exact a heavy toll on\nthe health and socio-economic development of people in some developing\ncountries.<\/p>\n\n\n\n<p>Over the past fifteen or so years, a growing number of PDPs have been established which aim to accelerate the development of new medical products by tipping the balance of risk and cost of investment in new product development towards the state. These include the WHO special programme for research and training in tropical diseases, the International AIDS Vaccine Initiative and the Medicines for Malaria venture. The Gates and Rockefeller foundations have set up several PDPs and the PDP Funders Group has made it possible for donors to club together and address certain diseases that would be beyond the means of a single sponsor to fund alone. However, an overall effect of the global financial crisis has nonetheless been to reduce the funding available for PDPs in the last few years. <\/p>\n\n\n\n<div class=\"wp-block-image is-style-default\"><figure class=\"aligncenter size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"704\" src=\"https:\/\/technopolis-group.com\/wp-content\/uploads\/2020\/02\/Drugs-1024x704.png\" alt=\"\" class=\"wp-image-10648\" srcset=\"https:\/\/technopolis-group.com\/wp-content\/uploads\/2020\/02\/Drugs-1024x704.png 1024w, https:\/\/technopolis-group.com\/wp-content\/uploads\/2020\/02\/Drugs-300x206.png 300w, https:\/\/technopolis-group.com\/wp-content\/uploads\/2020\/02\/Drugs-768x528.png 768w, https:\/\/technopolis-group.com\/wp-content\/uploads\/2020\/02\/Drugs-1536x1057.png 1536w, https:\/\/technopolis-group.com\/wp-content\/uploads\/2020\/02\/Drugs-2048x1409.png 2048w, https:\/\/technopolis-group.com\/wp-content\/uploads\/2020\/02\/Drugs.png 1101w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure><\/div>\n\n\n\n<p>The Dutch\nPDP Fund (2011-14) was able to piggyback on the work of the PDP Funders Group\nto help fund PDPs in neglected diseases, vaccine development, TB, diagnostics, microbiocides\nand reproductive health technologies. A lot of the effort went into clinical\ntrials \u2013 some of which were successful; others of which showed that potential\ninnovations were ineffective. In principle, funding such failures is necessary.\nReducing the cost of failure is a precondition for attracting the private\nsector into high-risk or potentially low-return product development.\nPersistence is needed, since successful new medicines take over a decade of\ntrials to reach the stage of FDA approval in the USA. Like the companies, the\nstate also has to take a portfolio approach and not to expect that every project\nwill \u2018succeed\u2019 in technical terms. <\/p>\n\n\n\n<p>PDPs\nfocusing on reproductive technologies such as women\u2019s condoms and on\ncost-reducing existing processes such as vaccine production had better success\nrates and produced results more quickly able to go into production than the clinical\ntrials. But clearly if sponsors were to focus all their attention on such PDPs\nthat promise shorter term success, important types of new product development\nwould not happen. <\/p>\n\n\n\n<p>One of the\nbenefits of the PDP approach is capacity building, through the training of\nlarge numbers of medical personnel associated with the trials. Perhaps\nunexpectedly, large pharmaceutical companies like GlaxoSmithKline (GSK),\nNovartis, Eli Lilly, have increased their commitment to combatting diseases\naffecting the poor and have set up their own public-private partnerships to\naccelerate drug discovery and development. <\/p>\n\n\n\n<p>Clearly PDPs\noffer opportunities to correct imbalanced market incentives and address\ndiseases that industry normally finds economically unattractive. But this is a type\nof intervention that needs patience \u2013 and, if it is to operate in the later\nstages of drug development, that can tolerate the big economic risks of\nlarge-scale clinical trials. Multi-funder arrangements like the PDP Funders\nGroup can become quite complex \u2013 but this may be a necessary cost to bear in\norder to share out high costs and risks among several funders.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The economics of the pharmaceuticals and other healthcare industries are [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[233,5],"tags":[],"solution":[],"sector":[75],"class_list":["post-18771","post","type-post","status-publish","format-standard","hentry","category-technopolitan-de","category-unkategorisiert","sector-health-life-sciences-de"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.1.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Can Product Development Partnerships tackle diseases of the poor? - Technopolis Group<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Can Product Development Partnerships tackle diseases of the poor? - Technopolis Group\" \/>\n<meta property=\"og:description\" content=\"The economics of the pharmaceuticals and other healthcare industries are [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/\" \/>\n<meta property=\"og:site_name\" content=\"Technopolis Group\" \/>\n<meta property=\"article:published_time\" content=\"2020-02-11T17:33:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-04-08T14:26:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/technopolis-group.com\/wp-content\/uploads\/2020\/02\/Drugs.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1101\" \/>\n\t<meta property=\"og:image:height\" content=\"758\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"cedric\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"cedric\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/\"},\"author\":{\"name\":\"cedric\",\"@id\":\"https:\/\/technopolis-group.com\/nl\/#\/schema\/person\/eeed59af0b9e4a5e3a50d148502a3256\"},\"headline\":\"Can Product Development Partnerships tackle diseases of the poor?\",\"datePublished\":\"2020-02-11T17:33:00+00:00\",\"dateModified\":\"2020-04-08T14:26:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/\"},\"wordCount\":645,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/technopolis-group.com\/wp-content\/uploads\/2020\/02\/Drugs-1024x704.png\",\"articleSection\":[\"Technopolitan\",\"Unkategorisiert\"],\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/\",\"url\":\"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/\",\"name\":\"Can Product Development Partnerships tackle diseases of the poor? - Technopolis Group\",\"isPartOf\":{\"@id\":\"https:\/\/technopolis-group.com\/nl\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/technopolis-group.com\/wp-content\/uploads\/2020\/02\/Drugs-1024x704.png\",\"datePublished\":\"2020-02-11T17:33:00+00:00\",\"dateModified\":\"2020-04-08T14:26:16+00:00\",\"author\":{\"@id\":\"https:\/\/technopolis-group.com\/nl\/#\/schema\/person\/eeed59af0b9e4a5e3a50d148502a3256\"},\"breadcrumb\":{\"@id\":\"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/#primaryimage\",\"url\":\"https:\/\/technopolis-group.com\/wp-content\/uploads\/2020\/02\/Drugs-1024x704.png\",\"contentUrl\":\"https:\/\/technopolis-group.com\/wp-content\/uploads\/2020\/02\/Drugs-1024x704.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/technopolis-group.com\/de\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Can Product Development Partnerships tackle diseases of the poor?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/technopolis-group.com\/nl\/#website\",\"url\":\"https:\/\/technopolis-group.com\/nl\/\",\"name\":\"Technopolis Group\",\"description\":\"Technopolis-group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/technopolis-group.com\/nl\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/technopolis-group.com\/nl\/#\/schema\/person\/eeed59af0b9e4a5e3a50d148502a3256\",\"name\":\"cedric\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/technopolis-group.com\/nl\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/497d412f48cec5d772f00904ec9eeece7ccdc8c4c13e9c38824de5ce441fab90?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/497d412f48cec5d772f00904ec9eeece7ccdc8c4c13e9c38824de5ce441fab90?s=96&d=mm&r=g\",\"caption\":\"cedric\"},\"url\":\"https:\/\/technopolis-group.com\/de\/author\/cedric\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Can Product Development Partnerships tackle diseases of the poor? - Technopolis Group","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/","og_locale":"de_DE","og_type":"article","og_title":"Can Product Development Partnerships tackle diseases of the poor? - Technopolis Group","og_description":"The economics of the pharmaceuticals and other healthcare industries are [&hellip;]","og_url":"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/","og_site_name":"Technopolis Group","article_published_time":"2020-02-11T17:33:00+00:00","article_modified_time":"2020-04-08T14:26:16+00:00","og_image":[{"width":1101,"height":758,"url":"https:\/\/technopolis-group.com\/wp-content\/uploads\/2020\/02\/Drugs.png","type":"image\/png"}],"author":"cedric","twitter_card":"summary_large_image","twitter_misc":{"Verfasst von":"cedric","Gesch\u00e4tzte Lesezeit":"3\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/#article","isPartOf":{"@id":"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/"},"author":{"name":"cedric","@id":"https:\/\/technopolis-group.com\/nl\/#\/schema\/person\/eeed59af0b9e4a5e3a50d148502a3256"},"headline":"Can Product Development Partnerships tackle diseases of the poor?","datePublished":"2020-02-11T17:33:00+00:00","dateModified":"2020-04-08T14:26:16+00:00","mainEntityOfPage":{"@id":"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/"},"wordCount":645,"commentCount":0,"image":{"@id":"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/#primaryimage"},"thumbnailUrl":"https:\/\/technopolis-group.com\/wp-content\/uploads\/2020\/02\/Drugs-1024x704.png","articleSection":["Technopolitan","Unkategorisiert"],"inLanguage":"de","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/","url":"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/","name":"Can Product Development Partnerships tackle diseases of the poor? - Technopolis Group","isPartOf":{"@id":"https:\/\/technopolis-group.com\/nl\/#website"},"primaryImageOfPage":{"@id":"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/#primaryimage"},"image":{"@id":"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/#primaryimage"},"thumbnailUrl":"https:\/\/technopolis-group.com\/wp-content\/uploads\/2020\/02\/Drugs-1024x704.png","datePublished":"2020-02-11T17:33:00+00:00","dateModified":"2020-04-08T14:26:16+00:00","author":{"@id":"https:\/\/technopolis-group.com\/nl\/#\/schema\/person\/eeed59af0b9e4a5e3a50d148502a3256"},"breadcrumb":{"@id":"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/#primaryimage","url":"https:\/\/technopolis-group.com\/wp-content\/uploads\/2020\/02\/Drugs-1024x704.png","contentUrl":"https:\/\/technopolis-group.com\/wp-content\/uploads\/2020\/02\/Drugs-1024x704.png"},{"@type":"BreadcrumbList","@id":"https:\/\/technopolis-group.com\/de\/can-product-development-partnerships-tackle-diseases-of-the-poor\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/technopolis-group.com\/de\/"},{"@type":"ListItem","position":2,"name":"Can Product Development Partnerships tackle diseases of the poor?"}]},{"@type":"WebSite","@id":"https:\/\/technopolis-group.com\/nl\/#website","url":"https:\/\/technopolis-group.com\/nl\/","name":"Technopolis Group","description":"Technopolis-group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/technopolis-group.com\/nl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/technopolis-group.com\/nl\/#\/schema\/person\/eeed59af0b9e4a5e3a50d148502a3256","name":"cedric","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/technopolis-group.com\/nl\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/497d412f48cec5d772f00904ec9eeece7ccdc8c4c13e9c38824de5ce441fab90?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/497d412f48cec5d772f00904ec9eeece7ccdc8c4c13e9c38824de5ce441fab90?s=96&d=mm&r=g","caption":"cedric"},"url":"https:\/\/technopolis-group.com\/de\/author\/cedric\/"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-12 02:20:00","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/technopolis-group.com\/de\/wp-json\/wp\/v2\/posts\/18771","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technopolis-group.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technopolis-group.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technopolis-group.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technopolis-group.com\/de\/wp-json\/wp\/v2\/comments?post=18771"}],"version-history":[{"count":0,"href":"https:\/\/technopolis-group.com\/de\/wp-json\/wp\/v2\/posts\/18771\/revisions"}],"wp:attachment":[{"href":"https:\/\/technopolis-group.com\/de\/wp-json\/wp\/v2\/media?parent=18771"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technopolis-group.com\/de\/wp-json\/wp\/v2\/categories?post=18771"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technopolis-group.com\/de\/wp-json\/wp\/v2\/tags?post=18771"},{"taxonomy":"solution","embeddable":true,"href":"https:\/\/technopolis-group.com\/de\/wp-json\/wp\/v2\/solution?post=18771"},{"taxonomy":"sector","embeddable":true,"href":"https:\/\/technopolis-group.com\/de\/wp-json\/wp\/v2\/sector?post=18771"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}